The management team have extensive knowledge of histology, immunohistochemistry and image analysis techniques and have considerable experience in the development and integration of translational biomarker strategies into drug discovery programs.
Chief Scientific Officer & Co-founder
Lorcan is an image analysis expert who previously spent 10 years in the pharmaceutical industry as a group leader (Organon, Schering-Plough, Merck & Co.). He led a group responsible for performing histology, immunohistochemistry / image analysis and he has considerable experience in developing translational biomarker strategies for projects across various therapeutic areas. He is a Prince 2® qualified project manager and has extensive experience in study management.
Chief Operating Officer & Co-founder
John worked for a total of 15 years as a biology project leader for various pharmaceutical companies including AstraZeneca and Merck & Co. He has expertise in the integration of translational biomarkers into drug discovery programs and has considerable experience in developing in vitro, ex vivo and in vivo models involving image analysis across numerous therapeutic areas. He is a Prince2®-practitioner qualified project manager.
Clinical Operations Manager
Mark worked in the pharmaceutical industry for 30 years (Organon, Schering-Plough, Merck & Co.) using techniques such as in-situ hybridisation, histology and immunohistochemistry, image analysis and the Affymetrix platform. More recently, Mark was a team manager and study director with global responsibility for supporting and developing pre-clinical safety studies at Charles River.
Alison Bigley is a Fellow of the Institute of Biomedical Science and spent 25 years at AstraZeneca as an Associate Principal Scientist and Team Leader in Pathology. She established and led a global digital pathology platform which included programming in proprietary software, application development and GxP validation. Alison has considerable experience in histology, immunohistochemistry and imaging on projects across various therapeutic areas involving pre-clinical, safety and translational medicine.
Senior Business Development Manager
Keith has worked in the Pharmaceutical industry for over 25 years, with experience in large Pharma (AstraZeneca), Biotech (Mironid) and the contract services sector (Biopta & OracleBio). He has held positions of both scientific, project and people leadership, with experience across the drug Dx/Dv pipeline, from HTS through to early clinical development support, including biomarker and translational science studies.
Senior Client Services Manager
Emma has over 20 years of experience working within pre-clinical and clinical laboratories. She worked within the pharmaceutical industry for 10 years (Organon, Schering-Plough, Merck & Co.) where she was involved in in vitro and ex vivo assay development for multiple drug discovery programs. Prior to this Emma worked as a Biomedical Scientist and more recently as a Research Scientist within Great Glasgow and Clyde NHS Trust, where she was responsible for a number of multicenter clinical research studies, coordinating sample receipt, registration and processing of clinical trial samples.
OracleBio's Quantitative Digital Pathology Services
Reasons Why Our Clients Choose to Work With OracleBio
Stay up to date with OracleBio
Subscribe to our mailing list to stay informed about news, webinars, events and more